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Abstract The recent discovery of genes involved in
familial forms of nephrotic syndrome represents a break-
through in nephrology. To date, 15 genes have been
characterized and several new loci have been identified,
with a potential for discovery of new genes. Overall, these
genes account for a large fraction of familial forms of
nephrotic syndrome, but they can also be recognized in 10–
20% of sporadic cases. These advances increase diagnostic
and therapeutic potentials, but also add higher complexity
to the scenario, requiring clear definitions of clinical,
histopathological and molecular signatures. In general,
genetic forms of nephrotic syndrome are resistant to
common therapeutic approaches (that include steroids and
calcineurin inhibitors) but, in a few cases, drug response or
spontaneous remission suggest a complex pathogenesis.
Finally, syndromic variants can be recognized on the basis
of the associated extra-renal manifestations. In this educa-
tional review, clinical, histological and molecular aspects of
various forms of familial nephrotic syndrome have been
reviewed in an attempt to define a rational diagnostic
approach. The proposed model focuses on practical and
economic issues, taking into consideration the impossibility
of using genetic testing as starting diagnostic tool. The final
objective of this review is to outline a diagnostic flow-chart
for clinicians and geneticists and to generate a rational
scheme for molecular testing.
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Introduction
With an estimated [1] annual incidence of between 2.0 and
2.7 cases per 100,000 children in the USA and a cumulative
prevalence of 16 per 100,000 [2, 3], idiopathic nephrotic
syndrome (NS) is the prevailing glomerular disease in
children. It is defined as the association of gross proteinuria
with hypoalbuminemia, edema and hyperlipidemia, a
condition that usually requires prolonged and combined
treatments, and one that may recur over years. Nephrotic
syndrom appears to be a clinically heterogeneous disease
characterized by different histological variants [4–6] and
genetic determinants [7–9]. The recent discovery of genes
involved in idiopathic NS represents a milestone in
nephrology. Most of these genes code for structural
elements of the slit diaphragm and of podocyte cytoskel-
eton (NPHS1, NPHS2, CD2AP, TRCP6, ACTN4); others
are expressed in the glomerular basement membrane
(LAMB2) and in mitochondria (COQ2) (see Table 1). Yet
another group includes transcription factors necessary for
normal podocyte function and development (WT1,
LMX1B). A thorough definition of histopathological fea-
tures is crucial for a correct genetic approach to idiopathic
NS since, in many cases, a genotype–phenotype correlation
can help to address the underlying molecular defect.
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Nevertheless, there is wide overlap between different forms
and cases of uncommon associations, such as the presence
of diffuse mesangial sclerosis in patients with NPHS2
mutations or focal glomerulosclerosis in patients with
variants in the PLCE1 gene.
Even though the review of the histopathological aspects of
idiopathic NS is not within the scope of our educational review
and readers should refer to specialized papers [10–12], a few
remarks could facilitate comprehension. A distinction is
generally accepted between a first group that includes minimal
change disease (MCD), mesangial proliferation with deposi-
tion of IgM (MesIgM) and focal segmental glomerulosclerosis
(FSGS) as different stages of the same entity and a second one
only represented by diffuse mesangial sclerosis (DMS) [13]. It
is important to stress that FSGS is not a single condition but
includes five histological variants, i.e. collapsing FSGS, tip
lesion, cellular variant, perihilar lesions and a final one
without specified alterations. Recognizing these sub-categories
has diagnostic, therapeutic and prognostic implications.
Collapsing FSGS is, for example, usually associated with
human immunodeficiency virus (HIV) infection and with
mitochondrial defects, while the unspecified variant is often
associated with NPHS2 mutations. In the diagnostic flow-
chart used at Istituto Giannina Gaslini (Fig. 1), the definition
of renal histopathology plays a central role for addressing the
molecular approach. This scheme is applied to all children
presenting with NS in the first year of life and in children
between two and 14 years of age with steroid resistance.
Genetic variant associated with FSGS/MesIgM/MCD
There are several genes causing isolated FSGS/MesIgM/MCD
with both autosomal recessive (AR) (NPHS2) and dominant
(AR) (ACTN4, TRPC6) inheritance and other modes (such as
in the case of CD2AP), which are currently under investiga-
tion. Overall, recessive forms are more frequent than
dominant traits, and NPHS2 is by far the gene most
frequently implicated in FSGS.
NPHS2/podocin (AR) (OMIM#604766) The NPHS2 gene
codes for podocin, which is a raft-associated component of
Table 1 Principle genes involved in familial nephrotic syndrome and in associated syndromes












NPHS2 1q25–31 Podocin AR FSGS 604766
Nephrotic syndrome,
steroid-resistant type 3
PLCE1 10q23 Phospholipase C epsilon 1 AR DMS 610725
Denys–Drash syndrome WT1 11p13 Wilms tumor 1 gene AD DMS 194080
Frasier syndrome WT1 11p13 Wilms tumor 1 gene AD FSGS 136680
Focal segmental
glomerulosclerosis type 1
ACTN4 19q13 Alpha-Actinin 4 AD FSGS 603278
Focal segmental
glomerulosclerosis type 2
TRPC6 11q21–22 Transient receptor potential








SMARCAL1 2q34–q36 SWI/SNF-related, matrix-associated,
actin-dependent regulator of
chromatin, subfamily a-like protein 1
AR FSGS 242900
Pierson syndrome LAMB2 3p21 Laminin beta 2 AR FSGS 609049
COQ2 deficiency COQ2 4q21–q22 Parahydroxybenzoate-polyprenyltransferase AR FSGS,
Collapsing
607426






SCARB2/LIMP2 4q13–q21 Scavenger receptor class B, member 2 AR FSGS 254900
AR Autosomal recessive; AD autosomal dominant; DMS diffuse mesangial sclerosis; FSGS focal segmental glomerulosclerosis; OMIM Online
Mendelian Inheritance in Man database; SWI/SNF swItch/sucrose nonfermentable nucleosome remodeling complex
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the glomerular foot-process membrane where the protein is
localized at the insertion of the slit-diaphragm [8, 14, 15]
(GenBank NM_014625; NP_055440). Podocin belongs to
the stomatin domain family proteins, which are uniquely
expressed in the kidney glomeruli where they interact with
nephrin and CD2AP. Mutations in the NPHS2 gene have
been initially identified in families with AR-FSGS, where
they account for most familial nephrotic syndromes with
recessive inheritance [8]. Extensive data have also been
published on NPHS2 mutational screenings in patients with
sporadic NS with recessive inheritance [16–21], most of
whom are children with steroid resistance. Overall, NPHS2
mutations have been reported to account for a significant
proportion of all nephrotic patients, corresponding roughly
to 45–55% of familial forms and 8–20% of sporadic
disease, with variations according to the different patient
cohorts and the different sub-phenotypes studied. However,
the actual incidence is probably much higher if only
patients with a poor response to steroids and/or showing a
pathological picture of FSGS are considered. More than 40
NPHS2 mutations have been reported to date that involve
the whole length of the gene; these determine every kind of
alteration, including deletions, splice site, missense and
nonsense variants. The onset of proteinuria has been
reported to occur at different ages, but generally before
the 14th year of life. A few cases of congenital NS have
been described, including two families with double homo-
zygous p.R168H and p.P20L mutations [16, 19]. With
respect to a possible genotype–phenotype correlation, some
inferences can be drawn: (1) p.R138Q appears to be
associated with early onset NS (at 12±3 months of age in
15 patients) whereas p.V180M and p.R238S are associated
with a late onset form (at 129±12 months in seven
patients); (2) carriers of the association of p.R229Q variant
with other NPHS2 mutations present late onset proteinuria,
generally between the first and second decades of life; (3)
carriers of NPHS2 mutations generally do not respond to
drugs commonly used in NS, with the exception of four
partial responders to cyclosporin described by Ruf and
colleagues [18]; (4) progression to end stage renal failure is
rapid in all cases and usually occurs within the first decade
of life [21]. Data on histopathological phenotype are
available for 48 patients with homozygous or compound
heterozygous NPHS2 mutations and for 15 with p.R229Q
associated with another NPHS2 mutation. Focal segmental
glomerulosclerosis was the prevailing glomerular lesion in
39 patients of the former group and in 15 of the p.R229Q/
heterozygous NPHS2 cohort. Ten patients had milder renal
changes epitomized by mesangial proliferation with IgM
deposition in eight cases and minimal changes nephropathy
in two. Finally, a few cases presented DMS and one biopsy
showed a nonspecific C3 deposition [17, 18]. Therefore, the
variability of renal histopathological phenotype associated
with NPHS2 mutations limits in some way the possibility of
a simple diagnosis based on two diagnostic tests (histology
and NPHS2 sequence). A major confounder is represented
by the presence, even if unusual, of DMS, which can
complicate the molecular approach.
TRPC6/transient receptor potential cation channel, homolog
of 6 (AD) (OMIM#603965) The TRCP6 gene codes for a
glomerular slit diaphragm-associated channel that is re-
quired for normal renal function. It is implicated in several
biological functions, but mainly in intracellular ion homeo-
stasis and calcium entry into cells. TRCP6 was first
localized to chromosome 11q21–22 by Winn and col-
leagues [22] and then identified as a cause of FSGS in a
large pedigree study from New Zealand [23]. Subsequently,
Reiser and colleagues [24] confirmed TRPC6 mutations in
another five unrelated families of different ancestry in
which mutations were inherited following an AR mode
with reduced penetrance. Five of the described mutations
predicted an amino acid change—one in the ankyrin
domain, two in the N-terminal intracellular domain and
two in the C-terminal intracellular domain—and only one
generated a stop codon at the C terminus. Functional
studies of three families showed that TRPC6 mutations
increased the influx of calcium into cells. One likely
explanation is that increased intracellular calcium modifies
the contractile structure of podocytes or, alternatively, high
calcium may cause podocytopenia through apoptosis,
detachment or lack of proliferation. Clinical features related
















< 1 yrs and up to 14 yrs
in case of steroid resistance
Fig. 1 Diagnostic flow-chart in children with early onset nephrotic
syndrome (<1 year) or in patients <14 years demonstrating steroid
resistance. Steroid resistance was defined by lack of anti-proteinuric
effect after 45 days with prednisone 2 mg/kg and three pulses with
methyl-prednisolone 10 mg/kg. DMS Diffuse mesangial sclerosis,
FSGS focal segmental glomerulosclerosis, NPHS1 nephrin gene,
NPHS2 podocin gene, PLCE1 phospholipase C epsilon 1 gene, WT1
Wilm’s tumor 1 gene, COQ2 para-hydroxybenzoate-polyprenyl-
transferase gene, PDSS2 decaprenyl diphosphate syntase gene,
mtDNA mitochondrial DNA
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symptoms occur in the third–fourth decade of life and
usually consist of severe proteinuria that is always
associated with FSGS. Progression to end stage renal
failure has been reported in 50% of the patients [25].
ACTN4/Alpha-Actinin-4 (AD) (OMIM#603278) Mutations
of ACTN4, the gene coding for α-Actinin 4, cause a rare
form of familial autosomal-dominant NS with reduced
penetrance. The function of this protein is to crosslink actin
filaments and connect them to the glomerular basement
membrane. To date, six families and sporadic cases have
been reported [9, 26, 27], all showing a mild increase in
urine protein excretion during adolescence or early adult-
hood and slow progression to end stage renal failure in
some affected individuals. In all cases described to date, the
ACTN4 mutations were in close proximity (exon 8) and
predicted an amino acid change in the actin-binding
domain. This finding suggests the existence of a mutational
hot-spot that would facilitate, if confirmed in a larger
population, the molecular work-up. Classical FSGS is the
most frequent histopathologic lesion related to ACTN4
mutations, but one child showing the collapsing variant
associated with rapidly progressing NS in early childhood
has also been reported [27].
CD2AP/CD2-associated protein (AR/AD) (OMIM#607832)
CD2-associated protein (CD2AP) is an adapter molecule
originally identified as a ligand for the T cell-adhesion
protein CD2. It is an 80-kDa cytoplasmic protein expressed
in all tissues except the brain. In the kidney, CD2AP is
localized to podocytes. The results of experiments in mice
with targeted disruption of CD2AP [28] and functional
studies [29] strongly suggest that CD2AP is a putative gene
in inherited NS. A unique patient with a homozygous
truncating mutation of CD2AP (stop codon at amino acid
position 612) has been recently described by Löwik and
colleagues [30]. This patient had developed early onset NS
with a histological pattern sharing some features of FSGS
and diffuse mesangial sclerosis patterns. A few other
patients with NS and heterozygous mutations of CD2AP
have also been reported. In a first report based on the
results of their study on 45 African-Americans, Kim et al.
[31] described a heterozygous nucleotide variant resulting
in aberrant CD2AP splicing in two patients with idiopathic
FSGS and HIV infection. Three heterozygous mutations
(c.944A>T; c.1161A>G; c.1573delAGA) producing amino
acid changes (p.K301M, p.T374A) or a deletion in
functional domains (p.delG525), respectively, were found
in three unrelated patients in Italy [32], and the functional
consequences of these were studied in two. One mutation
(p.K301M) resulted in defective CD2–CD2AP interaction
and clustering; the other (c.1573delAGA) was associated
with the down-regulation of CD2AP and podocin glomer-
ular expression. All three patients presented overt protein-
uria with steroid NS at variable ages (one in adulthood; the
other two in childhood), and FSGS was the corresponding
histopathological finding. Haplo-insufficiency of CD2AP
due to heterozygous mutations may confer susceptibility to
glomerular disease and integrity, as suggested by experi-
ments in CD2AP heterozygous knockout mice [31].
Genetic variants associated with isolated DMS
Diffuse mesangial sclerosis is a common histopathological
feature in renal biopsies of patients with congenital NS. It is
characterized by mesangial expansion and sclerosis that
evolve towards obliteration of the capillary lumen and
contraction of the glomerular tuft. Typically, there is no cell
proliferation in DMS; rather, there is an accumulation of
collagen-like fibrils in the mesangium and glomerular
basement membrane, causing thickening. The immunoflu-
orescence is usually negative. Diffuse mesangial sclerosis
does not represent a single entity, but is associated with
several syndromic disorders, such as Denys–Drash, Gallo-
way–Mowat, Pierson, carbohydrate-deficient glycoprotein
syndrome type I (see below) and even with viral infections.
In some cases, such as in NS of the Finnish type, DMS is
associated with diffuse microcysts and has been described
separately from the pure glomerular form.
PLCE1/phospholipase C epsilon (AR) (OMIM #610725)
Phospholipase C epsilon is a cytoplasmatic enzyme that is
required during podocyte maturation. PLCE1 gene muta-
tions have been recently identified in association with
congenital NS in several families from Turkey and one
from Israel, and PCLE1 is currently considered to be a
major gene responsible for NS during the first year of life
[33]. Children lacking PCLE1 for truncating mutations
present DMS that is due to a complete block of glomerular
maturation at the 23rd gestational week. More recently,
PCLE1 truncating mutations were identified in ten of 35
children with isolated DMS (28.3%), suggesting that
PLCE1 mutations are a major cause of DMS [34]. A less
severe course characterized by FSGS and slower progres-
sion to end stage renal failure has been reported in patients
with PLCE1 missense mutations, implying a genotype–
phenotype correlation and suggesting the clinical relevance
of genetic testing [35]. It has also been proposed that renal
histopathological patterns reflect the different kidney
developmental stages at which PCLE1 activity is required.
According to this hypothesis, DMS results from a devel-
opmental arrest due to truncating PLCE1 mutations,
whereas FSGS is the phenotype arising from low-level or
dysfunctional PLCE1 in the case of less severe molecular
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defects [35]. A further unexpected finding was a complete
response to steroid treatment in a girl with a homozygous
truncating PLCE1 mutation [35]. It seems reasonable to
propose that, in this case, steroids could have activated
some cellular response downstream of PLCE1 that sub-
stitutes phospholipase in the immunosuppressive effect.
Congenital nephrosis of the Finnish type
NPHS1/nephrin (AR) (OMIM#256300) Nephrin is proba-
bly the most structurally important protein in podocytes
where it represents the major constituent of the slit-
diaphragm at the regulation site for ultra-filtration of
proteins. It is encoded by NPHS1, a 26-kb gene located
on chromosome 19q13.1 [36]. Mutations in NPHS1 cause
an AR disorder characterized by a congenital NS that is
common in Finland; for this reason it is called Finnish
nephropathy (FN). Finnish nephropathy is also present
outside Finland and, in a recent survey of 80 sporadic cases
[37], NPHS1 mutations accounted for 22.5% of nephrotic
cases in the first year of life and was second to only NPHS2
as a causal factor of NS. More than 90 NPHS1 mutations
have been identified so far [38, 39]. In Finland, most
patients have mutations in exons 2 and 26, defined as
Finmajor (80% of cases) and Finminor, respectively. These
mutations cause truncated proteins of 90 and 1109 amino
acids, respectively, leading to the absence of nephrin in the
slit-diaphragm. A variety of mutations (missense, nonsense,
splice, deletions and insertions) have been reported outside
Finland in association with variable phenotypes [7, 40].
Missense mutations, that are frequently observed outside
Finland cause a milder phenotype (see below). Molecular
studies demonstrated an altered subcellular distribution of
these mutant nephrins, which accumulate in endoplasmic
reticulum and do not reach the cell membrane [41, 42].
Renal histopathology in FN biopsies at 3 months of life
showed mixed glomerular and tubulointerstitial lesions.
Glomerular lesions vary from mesangial hypercellularity to
glomerular sclerosis and/or diffuse mesangial sclerosis.
Tubular aspects are more characteristic and include diffuse
cystic dilatations of proximal and distal tubules (also
known as microcysts); interstitial fibrosis and inflammation
are usually present and increase with age. Immunofluores-
cence is always negative and electron microscopy shows
foot process effacement and villous transformation [43, 44].
Nephrin staining provides a definitive diagnosis in those
cases with truncating mutations since the slit diaphragm,
that is mainly composed of nephrin, may be absent in non-
sclerotic glomeruli. This is particularly important for a
differential diagnosis between FN and other congenital
nephrotic syndromes since nephrin staining can help to
detect the underlying defect [45].
The disease is characterized by severe proteinuria often
present ‘in utero’ and almost always appearing in the first year
of life. Steroid and calcineurin inhibitor resistance and the
requirement for albumin infusion and parenteral nutrition
characterize this life-threatening condition. Disease course is
rapidly progressive, and end stage renal failure generally
occurs within the first decade of life. In rare cases, FN may
have amild phenotype. Patrakka and colleagues [46] described
a patient with compound heterozygous Finminor and missense
mutations who responded to indomethacin and angiotensin-
converting enzyme (ACE) inhibitors, and another four cases
with missense mutations associated with remittent proteinuria
have been reported in Japan [47] and in Germany [39].
A recent report by Philippe and colleagues [42]
emphasizes the occurrence of mild clinical phenotypes.
They described a good clinical outcome in six patients who
actually carried at least one severe mutation that in most
cases determined a truncating protein. Histology showed
MCD in five patients and FSGS in one patient; clinical
follow-up was characterized by a good anti-proteinuric
effect of corticosteroids alone or in association with
cyclosporin. One child had normal renal function at 6 years
of age despite the absence of therapy.
The co-existence of NPHS1 and NPHS2 mutations was
observed in a few patients in association with congenital
FSGS or FN [48]. This result underlines a functional link
between nephrin and podocin that is also supported by
cellular studies on their interaction [49]. The results of
molecular studies suggested that, in order to produce
congenital NS, a triple hit is required, with a homozygous
event in one gene and the third mutation acting as modifier
of the others. The renal phenotype in carriers of this defect
ranges from FN to congenital FSGS, thereby supporting the
theory that these disorders can be regarded as part of a
spectrum, with the resulting effect being determined by the
molecular background. These observations also highlight
that, in the presence of FSGS and/or DMS, the molecular
diagnosis should incorporate the analysis of both NPHS2
and NPHS1 according to a flow chart that starts with
NPHS1 in the case of FN, and NPHS2 in the case of FSGS.
Syndromic forms
Denys–Drash (OMIM#194080) and Frasier syndromes
(OMIM#136680) Denys–Drash (DDS) and Frasier syn-
dromes (FS) are caused by WT1 gene mutations. This gene
codes for a transcriptional factor (Wilms’ tumor suppressor
protein) of the zinc-finger protein family that is involved in
kidney and gonadal development. It consists of ten exons and
is localized on chromosome 11q13. It leads to four different
isoforms, depending on alternative splicing [50]. After birth,
WT1 protein expression is restricted to renal podocytes
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where it probably contributes to maintaining cellular differ-
entiation [51]. Germline heterozygous WT1 mutations have
been extensively reported in the literature as the cause of the
two predominant sporadic phenotypes, i.e. DDS and FS,
which are characterized by different combinations of NS with
genital anomalies and pseudo-hermaphroditism [52, 53].
WT1 is also known as the cause of sporadic and familial
Wilms tumor [50], which is the most common solid tumor in
childhood and represents a potential evolution of DDS.
Genetic variations and clinical phenotypes allow an easy
differentiation between DDS and FS since over 95% of DDS
carry missense mutations in exons 8 and 9, while FS is more
frequently associated with specific splice site mutations at
IVS9, resulting in the presence or absence of a tri-peptide of
lysine-threonine serine (KTS) in exon 9. In terms of renal
involvement, DDS is predominantly characterized by diffuse
mesangial sclerosis with early onset and rapid evolution to
end stage renal failure, while FS usually presents slowly
progressive FSGS, although rare variants with glomerular
basement membrane involvement have been reported [54].
The real impact of WT1 mutations in children with steroid
resistant nephrotic syndrome (SRNS) has been recently
evaluated by Ruf and colleagues [55] and in an extended
cohort by Mucha and colleagues [56]. These studies showed
an overall incidence of 7%, with a prevalence of FS over
DDS phenotypes. It was striking that only one female out of
eight with FS presented XY inversion and sexual anomalies
that have long been considered a key sign of the syndrome.
This finding strongly supports the need for the mutational
analysis of WT1 in children affected by NS with steroid
resistance in order to avoid potentially harmful therapeutic
interventions. An extension of screening studies to large
cohorts of children and adults with SRNS is the natural
consequence of the above findings. Aucella and colleagues
[57] screened 115 patients with SRNS and 86 with steroid
dependence (85 adults) for WT1 mutations, with results that
partially confirm the findings of Ruf and colleagues [55].
This study [57] also extends the basic histopathologic picture
of FS to unusual renal findings, describing two cases with
thinning of the basement membrane and with the presence of
foam cells in the interstitium that appear to represent the
prevalent early feature in FS patients.
Pierson syndrome (OMIM#609049) Pierson syndrome [58]
is caused by mutations in the LAMB2 gene that codes for
laminin β2, a protein widely expressed in the glomerular
basement membrane, retina, lens capsule and neuromuscu-
lar synapses [59]. The syndrome, characterized by micro-
coria and abnormal lens shape and cataract, is associated
with NS that develops ‘in utero’ or within the first 3 months
of life. The renal histopathologic lesion is DMS, and the
outcome is usually a rapid progression to renal failure. In
addition, patients surviving infancy develop blindness and
severe neurological deficits [60]. The classical form is
caused by truncating mutations of LAMB2 [61]. Missense
and non-truncating mutations of LAMB2 are associated with
a milder phenotype without microcoria or with minor
structural eye anomalies, always with histological evidence
of FSGS [62, 63]. Finally, LAMB2 missense and truncating
mutations have been reported in two cases presenting
congenital NS without any ocular anomalies [64], suggest-
ing that LAMB2 may be implicated in inherited NS more
frequently than expected.
Schimke immuno-osseous dysplasia (OMIM#242900) Schimke
immuno-osseous dysplasia is an AR condition character-
ized by spondyloepiphyseal dysplasia with T-cell immuno-
deficiency and glomerulosclerosis [65]. Hypothyroidism
and episodes of cerebral ischemia were found to be
associated in a fraction of patients [66]. In 2002, Boerkoel
and colleagues identified mutations of the SMARCAL1 gene
in 26 families with the disease, most of whom presented a
severe phenotype [67]. SMARCAL1 codes for a protein that
participates in DNA remodeling after replication. Schimke
immuno-osseous dysplasia is a clinically heterogeneous
disease since severity ranges from a very early onset and
death in the first years of life to milder forms that start in the
first decade of life and survive beyond the second. In this
disease, glomerulosclerosis evolves to end-stage renal failure
requiring replacement treatment and renal transplantation.
Action myoclonus–renal failure syndrome (OMIM#254900) Ac-
tion myoclonus–renal failure syndrome (AMRF) is an AR
condition characterized by progressive myoclonus epilepsy
associated with renal failure. Proteinuria is the hallmark and
first symptom of the disease. Age at onset is between 15 and
20 years, and glomerulosclerosis with focal collapse is the
usual histopathologic picture. Neurological symptoms, i.e.
tremor, action myoclonus, seizures and ataxia, develop at a
later stage and are produced by a characteristic deposition of
lysosomal storage material in the brain. SCARB2 is the gene
whose mutations are responsible for the disease. It codes for
a lysosomal integral membrane protein that has pleiotropic
molecular functions. Action myoclonus–renal failure syn-
drome is now considered a storage disease due to alterations
in lysosome functions and, like any other conditions
involving lysosomes, it is mainly characterized by degener-
ative lesions of the brain [68].
Nail–patella syndrome (OMIM#161200) Nail–patella syn-
drome, also known as osteo-onychodysplasia, is an AD
disorder classically producing dysplastic fingernails and
hypoplastic or absent patella in association with renal
defects that have been found in 40% of cases [69].
Glomerular changes involve both podocyte foot-process
effacement [70] and thickening of the glomerular basement
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membrane as a result of the irregular deposition of fibrillar
collagen type III [71]. The disease is caused by mutations
of the LMX1B gene that codes for a transcription factor
active at a very early stage of podocyte development [70].
The Lmx1b gene knockout mice present a retarded
maturation of podocytes that do not develop foot-processes
nor express major slit-diaphragm genes, such as podocin
and nephrin. Alterations of the glomerular basement
membrane and of the endothelial fenestration suggest a
direct role of LMX1B at these sites [72].
Galloway–Mowat syndrome (OMIM#251300)
The Galloway-Mowat syndrome is a rare condition origi-
nally described in 1968 in three sibs with the triad of
congenital NS, microcephaly and hiatus hernia [73]. It is
considered to be an AR disorder whose causative gene(s)
are still unknown. Clinical features are generally repre-
sented by early onset NS with strict resistance to steroids
and a poor prognosis [74]. Milder variants have also been
reported, with the first renal symptom appearing after 10
years of age [75]. Renal pathology is also heterogeneous
and varies from minimal changes to capillary proliferation,
glomerulosclerosis and, in some cases, DMS [76].
Mitochondrial cytopathies
tRNALeu(UUR) Nephrotic syndrome may be part of a gener-
alized defect induced by mutations in mitochondrial DNA
(mtDNA). This condition preferentially affects the muscle
and the nervous system but may also extend to the kidney. A
typical example is the A3243G transition in the tRNALeu(UUR)
gene that is classically associated with MELAS syndrome
(mitochondrial myopathy, encephalopathy, lactic acidosis,
stroke episodes and occasional tubular defects) [77]. This
mutation has also been found to be associated with FSGS in
patients without any other sign of MELAS [78]. The clinical
phenotype in children with an isolated renal defect is
characterized by variable proteinuria, from mild to severe,
with resistance to steroids and slow progression to end stage
renal failure.
CoQ10 deficiency: COQ2 and PDSS2 (OMIM#607426) Con-
genital deficiency of coenzyme Q10 (CoQ10) includes a
group of AR anomalies that are primarily characterized by
neurological and muscular symptoms [79, 80] but may also
present with isolated NS [81]. They are produced by
mutations of genes coding for enzymes of the CoQ10
pathway, only a part of which have been identified. COQ2
is one of these genes. It codes for para-hydroxybenzoate-
polyprenyl-transferase (EC 2.5.1.39), which catalyzes pre-
nylation of para-hydroxybenzoate [82]. Mutations of COQ2
have been reported in association with isolated NS in two
children and/or as part of a multi-organ defect producing
progressive encephalopathy with muscular hypotonia and
optic nerve atrophy in two other children. Severe NS with
rapid progression to terminal renal failure is a predominant
clinical feature. Renal histopathology was characterized by
collapsing glomerulopathy and severe extracapillary prolif-
eration in two cases, while FSGS was found in two
siblings. Ultrastructural findings showed dysmorphic mito-
chondria with electron-lucent bodies in all cases and
oncocyte-like aspects in a few. Biochemical analysis
showed a decreased complex [II + III] activity in the renal
cortex and skeletal muscle [81].
PDSS2 is the second gene implicated in CoQ10 deficien-
cy syndrome. It codes for decaprenyl diphosphate synthase,
the first enzyme of the CoQ10 biosynthetic pathway [83].
The first and unique case with compound heterozygous
mutations of PDSS2 described to date presented [35] with
severe Leigh syndrome characterized by seizures, hypotonia,
cortical blindness and NS [83]. Biochemical analysis
performed in muscles and fibroblasts demonstrated de-
creased complex [II + III] activity and a severe defect in
decaprenyl diphosphate synthase.
Literature data indicate that children with congenital NS
and encephalopathy should be screened for primary defect
in CoQ10 biosynthesis. Cases with isolated renal defect, i.e.
collapsing glomerulopathy or crescentic glomerulosclerosis,
should also be screened. Molecular analysis of both COQ2
and PDSS2 is now available in several laboratories and
should be performed in those patients with the above
phenotypes. Therapy with coenzyme Q10 should be started
very early since it may completely resolve NS [84] and
actually represents the unique example of successful
therapy for mitochondrial defects.
Drug-responsive variants of NS
Steroid-sensitive NS (SSNS) may occasionally occur in
association with mutations of some of the genes mentioned
above, but a good response to therapy is, in general,
considered to be a rare event [42, 85, 86]. Two examples of
inherited conditions responsive to steroids are the few cases
with mild mutations of nephrin recently reported by
Philippe and colleagues [42] and the unique girl carrying
homozygous truncating PLCE1 mutations [35].
Familial aggregates and kindred with SSNS in geo-
graphical isolates have been described, suggesting a
potential genetic origin. Very little data on molecular
genetics of SSNS are available in the literature. A
genome-wide scan for linkage has been recently conducted
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in 11 families with an AR trait, one of which was a
consanguineous kindred from Germany. The first locus for
SSNS was identified on chromosome 2p12–13.2 in an
interval of 3.6 Mb that contains approximately 60 known
genes and 25 predicted genes [87]. The characterization of
the first gene involved in NS responsive to steroids would
represent a critical step in the definition of the underlying
mechanism of non-inherited forms of the disease.
Recurrence of disease after renal transplantation
The underlying factors for post-transplant recurrence of
proteinuria in FSGS remains an enigma. Patients with the
sporadic variety of FSGS who have known homozygous or
complex heterozygous traits present a low recurrence rate
[88], and this appears to be a logical consequence of the
fact that proteinuria is originally due to the inherited defect
in the native organ while the grafted kidney is normal. This
aspect has mostly been considered in patients with NPHS2
mutations. An original report by Bertelli and colleagues
[89] described two patients with homozygous or compound
heterozygous mutations of NPHS2 (22% of those who
received a renal graft), and in both cases the episode had a
mild clinical impact with favorable outcome. Another two
cases of recurrent FSGS have been recently described: one
had the NPHS2 mutation [90] and the other had the WT1
mutation (IVS9+4C>T) and Frasier syndrome [91]. More
recently, Sanna-Cherchi and colleagues [92] described a
pedigree with AD FSGS of unknown origin in which the
index case presented post-transplant recurrence of severe
proteinuria and MCD. The identification of families with
AD transmission and recurrence of disease has provided the
chance to identify extra-renal factors involved in the
pathogenesis of sporadic forms of FSGS. We now have
the opportunity to consider post-transplant recurrence in a
larger population and to compare the original data by
Bertelli and colleagues [89] with other study cohorts [18,
19]. Collectively (including the study by Bertelli), data are
available for 65 carriers of homozygous or compound
heterozygous NPHS2 mutations, and the post-transplant
recurrence of proteinuria was documented in five of these
(7.7%). It is worth reporting that one child with the
homozygous p.L347X mutation described by Ruf and
colleagues [18, 93] and another one with homozygous p.
R138X described by Weber and colleagues [19] received
the kidney from their mother, who was an obligatory
healthy heterozygous carrier. The first child had recurrence
of proteinuria on day 7 from the graft and responded within
1 week to plasmapheresis. The second child presented
nephrotic range proteinuria 2 years after the allograft. While
the low number of patients with a single NPHS2 mutation
does not allow any definite conclusion to be drawn, these
results strongly suggest that the rate of recurrence in patients
with NPHS2 homozygous or compound heterozygous
mutations is low. Grafts from obligatory carriers of NPHS2
mutations, such as parents of affected individuals, should be
avoided because of the higher risk of recurrence of FSGS.
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2. Genes involved in NS code most frequently for proteins of








d) With Finnish nephropathy
4. PLCE1 usually causes DMS
a) In most cases
b) The association has never been reported
c) Is more frequently associated with FSGS
d) Is usually associated with hermaphroditism
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